A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice

Cancer Immunology Research

Volumn 5, Issue 6, 2017, Pages 468-479

  Foote, Jeremy B ^a,b   Kok, Marleen ^a   Leatherman, James M ^a   Armstrong, Todd D ^a,c   Marcinkowski, Bridget C ^a   Ojalvo, Lureen S ^a,b   Kanne, David B ^d   Jaffee, Elizabeth M ^a,c   Dubensky, Thomas W ^d   Emens, Leisha A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Aduro BioTech Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADU S 100; ANTINEOPLASTIC AGENT; BETA INTERFERON; CD134 ANTIGEN; CHEMOKINE; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; CYCLIC AMP DERIVATIVE; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOMODULATING AGENT; INTERFERON; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MEMBRANE PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OAS1G PROTEIN; OAS2 PROTEIN; OASL2 PROTEIN; OX40 RECEPTOR AGONIST; PROGRAMMED CELL DEATH 1 LIGAND 1 INHIBITOR; PROGRAMMED DEATH 1 LIGAND 1; RANTES; STIMULATOR OF INTERFERON GENE PROTEIN; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; CD274 PROTEIN, MOUSE; MPYS PROTEIN, MOUSE; TNFRSF4 PROTEIN, MOUSE;

AGONIST POTENCY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CLEARANCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; FVB/N MOUSE; GENE EXPRESSION; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MEDIAN SURVIVAL TIME; MONOTHERAPY; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; ONCOLOGICAL PARAMETERS; SINGLE DRUG DOSE; STRAIN DIFFERENCE; T LYMPHOCYTE ACTIVATION; TUMOR CLEARANCE; TUMOR IMMUNITY; TUMOR REGRESSION; AGONISTS; ANIMAL; IMMUNOLOGY; NEOPLASM; PATHOLOGY; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; B7-H1 ANTIGEN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE PROTEINS; MICE, TRANSGENIC; NEOPLASMS; RECEPTORS, OX40; TUMOR BURDEN;

EID: 85020641723     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-16-0284     Document Type: Article

References (30)

1. Pages F, Galon J, Fridman WH. The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol 2008;84:981-7.
2. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8 lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011;29:1949-55.
3. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7.
4. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
5. Gajewski TF.Failure at the effector phase:immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007;13:5256-61.
6. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumorCD8T cell responses through CD8{alpha} dendritic cells. J Exp Med 2011;208:2005-16.
7. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011;208: 1989-2003.
8. Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014;41:830-42.
9. Diner EJ, Burdette DL, Wilson SC, Monroe KM, Kellenberger CA, Hyodo M, et al. The innate immuneDNAsensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep 2013;3:1355-61.
10. Gao P, Ascano M, Zillinger T, Wang W, Dai P, Serganov AA, et al. Structurefunction analysis of STING activation by c[G(20, 50)pA(30, 50)p] and targeting by antiviral DMXAA. Cell 2013;154:748-62.
11. Dubensky TW Jr., Kanne DB, Leong ML. Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants. Ther Adv Vaccines 2013;1:131-43.
12. Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep 2015; 11:1018-30.
13. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992;89:10578-82.
14. Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, et al. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 2001;61:880-3.
15. Uram JN, Black CM, Flynn E, Huang L, Armstrong TD, Jaffee EM. Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response. J Immunol 2011;186:3847-57.
16. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, et al. Recruitment of latent pools of high-avidity CD8() T cells to the antitumor immune response. J Exp Med 2005;201:1591-602.
17. Murata S, Ladle BH, Kim PS, Lutz ER, Wolpoe ME, Ivie SE, et al. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8 T cell tolerance to an endogenous tumor antigen. J Immunol 2006;176:974-83.
18. Black CM, Armstrong TD, Jaffee EM. Apoptosis-regulated low-avidity cancer-specific CD8() T cells can be rescued to eliminate HER2/neuexpressing tumors by costimulatory agonists in tolerized mice. Cancer Immunol Res 2014;2:307-19.
19. Weiss VL, Lee TH, Song H, Kouo TS, Black CM, Sgouros G, et al. Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. PLoS One 2012;7:e31962.
20. Manning EA, Ullman JG, Leatherman JM, Asquith JM, Hansen TR, Armstrong TD, et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 2007;13:3951-9.
21. Demaria O, De Gassart, A, Coso S, Gestermann N, Di Domizio J, Flatz L, et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc Natl Acad Sci U S A 2015; 112:15408-13.
22. Baird JR, Friedman D, Cottam B, Dubensky TW Jr., Kanne DB, Bambina S, et al. Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors. Cancer Res 2016;76: 50-61.
23. Waddell SJ, Popper SJ, Rubins KH, Griffiths MJ, Brown PO, Levin M, et al. Dissecting interferon-induced transcriptional programs in human peripheral blood cells. PLoS One 2010;5:e9753.
24. Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI, et al. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 2000;60:3569-76.
25. Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez- Forero I, Labiano S, et al. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res 2013;19:6151-62.
26. Cheung AF, Dupage MJ, Dong HK, Chen J, Jacks T. Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Res 2008;68:9459-68.
27. Terawaki S, Chikuma S, Shibayama S, Hayashi T, Yoshida T, Okazaki T, et al. IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol 2011; 186:2772-9.
28. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Upregulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8() T cells. Sci Transl Med 2013; 5:200ra116.
29. Ohkuri T, Ghosh A, Kosaka A, Zhu J, Ikeura M, David M, et al. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res 2014; 2:1199-208.
30. Fu J, Kanne DB, Leong M, Glickman LH, McWhirter SM, Lemmens E, et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med 2015;7:283ra52.